PHAT
Phathom Pharmaceuticals, Inc.Company with tickers: PHAT
CIK
1783183
CUSIP
71722W107
Shares Outstanding
79,755,953
Website
https://www.phathompharma.com
13F Activity (30d)
86 filings
86 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $58,301,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $11,996,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Gross Profit | $46,305,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Operating Expenses | $61,782,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Research & Development | $7,771,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Operating Income | $-15,477,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Net Income | $-30,369,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Basic) | $-0.37 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Diluted) | $-0.37 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $55,252,000 | $175,110,000 |
By Product & Service (USD)
| Component | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Voquezna Product | $55,300,000 | $175,100,000 |